tetano
Editor, Senior Moderator
J Exp Med
. 2020 Sep 7;217(9):e20201342.
doi: 10.1084/jem.20201342.
Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
Lars M Koenig[SUP] 1 [/SUP], Daniel F R Boehmer[SUP] 1 [/SUP], Philipp Metzger[SUP] 1 [/SUP], Max Schnurr[SUP] 1 [/SUP], Stefan Endres[SUP] 1 [/SUP], Simon Rothenfusser[SUP] 1 [/SUP]
Affiliations
Abstract
An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.
. 2020 Sep 7;217(9):e20201342.
doi: 10.1084/jem.20201342.
Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
Lars M Koenig[SUP] 1 [/SUP], Daniel F R Boehmer[SUP] 1 [/SUP], Philipp Metzger[SUP] 1 [/SUP], Max Schnurr[SUP] 1 [/SUP], Stefan Endres[SUP] 1 [/SUP], Simon Rothenfusser[SUP] 1 [/SUP]
Affiliations
- PMID: 32678432
- DOI: 10.1084/jem.20201342
Abstract
An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.